Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

@article{Ili2014CurrentCF,
  title={Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?},
  author={Marius Ili{\'e} and V{\'e}ronique Hofman and Elodie Long and Olivier Bordone and Eric Selva and Kevin Washetine and Charles Hugo Marquette and Paul Hofman},
  journal={Annals of translational medicine},
  year={2014},
  volume={2 11},
  pages={107}
}
The practice of "liquid biopsy" as a diagnostic, prognostic and theranostic tool in non-small cell lung cancer (NSCLC) patients is an appealing approach, at least in theory, since it is noninvasive and easily repeated. In particular, this approach allows patient monitoring during treatment, as well as the detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance. However, clinical routine practice is slow to adopt… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 74 references

Cancer statistics ,

  • A Gower, Y Wang, G Giaccone
  • 2014

Circulating cellfree DNA in cancer

  • P Pinzani, F Salvianti, C Orlando
  • Methods Mol Biol
  • 2014
2 Excerpts

Efficiency of the Therascreen(R) RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas

  • A Vallée, AG Le Loupp, MG. Denis
  • Clin Chim Acta 2014;429:8-11
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…